Together, We Got This
Access to routine and accurate testing for K-12 schools and colleges is key to safely returning students to campus. Using Simoa® technology, CLIA labs can easily address these high throughput testing needs and help our kids get back to class.
Sensitivity of molecular testing with the efficiency of immunoassays
Simoa (Single Molecule Array) technology provides greater than 100X increase in sensitivity compared to other FDA authorized antigen tests.
Simoa SARS-CoV-2 N Protein Antigen Test Sensitivity White Paper
Automated Sample-Answer Workflow Supporting 1,000 Tests Per Day
The HD-X Analyzer automates the sample processing and analysis with minimal hands-on time to increase lab productivity and reduce operator-based variability.
Robust Detection of Variants of Concern
Flexibility to Support Multiple Specimen Types
Authorized by FDA under EUA for nasopharyngeal swab specimens. Validated for use with anterior nasal swabs and FDA has allowed implementation of the anterior nasal swabs under the Notification pathway. Designed and tested for saliva and dried blood spots, with EUA application submitted and pending FDA review
Supported as an NIH RADx Company
In response to the pandemic, the National Institutes of Health (NIH) launched the Rapid Acceleration of Diagnostics (RADx) initiative in 2020 fund innovative companies like Quanterix to accelerate the development and deployment of vital new COVID-19 testing solutions development and deployment of vital new COVID-19 testing solutions